Sanofi to Acquire Dynavax for $2.2 Billion, Expanding Its Vaccine Portfolio
We from the global health and business community note a major deal: on December 24, 2025, French pharma Sanofi agreed to buy U.S. vaccine maker Dynavax for $2.2 billion. The deal will boost Sanofi’s adult vaccine portfolio and is expected to close in early 2026 after regulatory approvals.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
